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Abstract
Background: A low eicosapentaenoic acid (EPA) to arachidonic acid (AA) ratio is a known risk for acute coronary
syndrome (ACS). However, the association between the docosahexaenoic acid (DHA) to AA ratio and ACS remains
unclear. This study aimed to assess the association between the DHA/AA ratio and ACS by patient characteristics.
Methods: We enrolled 1733 patients and evaluated the serum levels of polyunsaturated fatty acids in 5 cardiology
departments in a metropolitan area of Japan. We assessed the relationship between the DHA/AA ratio (median
cut-off value: 0.903) and ACS according to the following 10 subgroups: sex, age, diabetes mellitus, hypertension,
dyslipidemia, smoking history, family history of ischemic heart disease, chronic kidney disease, obesity, and history
of coronary revascularization.
Results: Interaction tests in the 10 subgroup analyses revealed a significant difference for adjusted log odds ratios
between male and females (p = 0.01), and those with and without hypertension (p = 0.06). Especially in the
subgroup based on sex difference, a high DHA/AA ratio was significantly associated with a low risk of ACS among
men (adjusted odds ratio = 0.389; 95 % confidence interval: 0.211–0.716). In contrast, a reverse association was
found among women, although this was not statistically significant (adjusted odds ratio = 3.820; 95 % confidence
interval: 0.718–20.325).
Conclusions: The association between the DHA/AA ratio and ACS differed by clinical characteristic. Notably,
patients with a low DHA/AA ratio had a higher risk of ACS than those with a high DHA/AA ratio, and this was
significant for men in particular.
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Background
Previous studies have demonstrated the beneficial effect
of omega-3 polyunsaturated fatty acids (PUFAs) for pre-
venting coronary events [1, 2]. In particular, several stud-
ies have reported that the eicosapentaenoic acid (EPA)
to arachidonic acid (AA) ratio is a useful marker for esti-
mating the risk of coronary events [3–5]. We recently
reported that a low EPA/AA ratio was significantly asso-
ciated with acute coronary syndrome (ACS) in a cohort
of 1119 participants without any history of coronary re-
vascularization or myocardial infarction [6]. However,
the association between the docosahexaenoic acid
(DHA) to AA ratio and coronary artery disease (CAD),
particularly ACS, remains unclear. Although EPA and
DHA are both omega-3 PUFAs, each may have different
physiological and pharmacological effects [7]. We hy-
pothesized that the effect of DHA/AA ratio for ACS
could differ by patient characteristics, and that this dif-
ference might attenuate the association between the
DHA/AA ratio and ACS when conducting analyses by
ignoring the statistical interaction of the characteristics.
Methods
Study population
The present study was a multicenter observational
cross-sectional study performed at four university hospi-
tals and one community hospital located in Tokyo, Japan
[6]. We enrolled 1733 patients who had their serum
PUFA levels evaluated at these five centers from January
2004 to May 2011. The cohort included 151 patients
with ACS and 1582 patients without ACS. Acute myo-
cardial infarction was defined as an increase in the creat-
ine kinase MB fraction or troponin T in patients with
ischemic symptoms and/or typical electrocardiographic
ST elevation. Unstable angina was defined as angina at
rest or accelerated exertional angina combined with typ-
ical electrocardiographic ST-changes and an increased
requirement for anti-ischemic therapy [8]. Patients were
excluded if they were receiving hemodialysis or were
currently taking EPA, and if they had concomitant con-
gestive heart failure, severe liver dysfunction, or other
systemic diseases, including malignancy and collagen
disease. This study was approved by the Institutional
Ethics Committees of each hospital, and all subjects gave
informed consent.
Measurements
We assessed the coronary risk factors and evaluated
serum EPA, DHA, dihomo-gamma-linolenic acid
(DGLA), and AA levels. We also measured the following
laboratory parameters: total cholesterol, triglycerides
(TG), low-density lipoprotein (LDL)-cholesterol, high-
density lipoprotein (HDL)-cholesterol, hemoglobin A1c,
serum creatinine (Cr), and estimated glomerular filtration
rate (eGFR). The eGFR was calculated on the basis of the
Japanese equation that utilizes serum Cr, age, and sex, as
follows: eGFR (ml/min/1.73 m2) = 194 × Cr−1.094 × age
−0.287 (female × 0.739) [9]. Serum EPA, DHA, DGLA, and
AA levels were measured at an external laboratory (SRL,
Inc., Tokyo, Japan). Blood samples were obtained from pa-
tients either during admission or at the laboratory of the
outpatient clinic.
Statistical analyses
We assessed the relationship between the DHA/AA ratio
(at a median cut-off value of 0.903) and ACS in 10 dif-
ferent subgroups as follows: sex, age, diabetes mellitus
(DM), hypertension (HT), dyslipidemia (DL), smoking
history, family history of ischemic heart disease (IHD),
chronic kidney disease (CKD), obesity defined as body
mass index (BMI) ≥25, and history of coronary revascu-
larization (percutaneous coronary intervention or coron-
ary artery bypass grafting). To adjust for clinical
characteristics other than the stratification variable for
each subgroup, we fitted multivariable logistic regression
models that included the following variables: age, BMI,
serum Cr (continuous covariates), sex, smoking history,
family history of IHD, HT, DM, or DL, a history of cor-
onary revascularization (binary covariates), and the EPA/
AA ratio. The EPA/AA ratio was divided into three ter-
tiles for the present study, in line with our previous re-
port that analyzed data extracted from the same study
population [6]. Patients with missing data for any vari-
able were excluded from the multivariable analysis. The
alpha level for statistical tests was set at 0.05 and all con-
fidence intervals were presented with their 95 % confi-
dence levels.
The differences in associations (adjusted log odds ra-
tios) between DHA/AA ratio and ACS from different
subgroups were evaluated by the approximate formula
for testing interaction [10]. Because of the limited power
of the interaction test [11] and its nature as a prelimin-
ary test for statistical modeling [12], we considered a sig-
nificance level of 0.10 to reflect a significant difference
between subgroups. All analyses were performed with
SAS version 9.2 (Cary, NC, USA).
Results
Tables 1 shows the clinical characteristics and laboratory
data for all patients by high and low DHA/AA ratios
(≥0.903 and <0.903, respectively). Among the high DHA/
AA ratio group (n = 867), the incidence of ACS was
7.50 % (65/867), compared with 9.93 % (86/866) in the
low DHA/AA ratio group (n = 866). The crude odds ratio
for ACS was 0.735 [95 % confidence interval (CI): 0.525,
1.030, p = 0.07] based on a DHA/AA ratio ≥0.903 versus
<0.903. The adjusted odds ratio from the multivariable
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logistic model including all variables as regression covari-
ates was 0.523 (95 % CI: 0.300, 0.910, p = 0.022).
In the high DHA/AA ratio group, the patient age, TG
levels, and the prevalence of HT and smoking were sig-
nificantly higher than in the low DHA/AA ratio group,
whereas, the opposite was found in these groups regard-
ing the HDL-cholesterol levels. In addition, the use of
statins was significantly lower, and the use of antiplatelet
agents was significantly higher in the high DHA/AA ra-
tio group than in the low DHA/AA ratio group.
Serum AA level was significantly higher in patients
with statin treatment than in patients without statin
treatment (160.3 ± 40.9 vs. 154.1 ± 57.6 μg/dl, P = 0.01).
Conversely, serum AA level was significantly lower in
patients with antiplatelet agent treatment (152.5 ± 38.4
vs. 165.7 ± 63.2 μg/dl, P < 0.01), beta blocker treatment
(152.9 ± 39.6 vs. 160.3 ± 54.7 μg/dl, P < 0.01), and
hypoglycemic agent treatment (151.9 ± 40.1 vs. 158.9 ±
51.7 μg/dl, P = 0.01) than in patients without these
treatments.
Table 1 Baseline clinical characteristics and laboratory data
All patients (n = 1733) High DHA/AA ≥0.903 (n = 867) Low DHA/AA <0.903 (n = 866) P-value
Age (years) 64.5 ± 11.3 67.1 ± 9.2 61.8 ± 12.5 <0.01a
Male 77.8 % 79.4 % 76.2 % 0.11
Body mass index (kg/m2) 24.4 ± 3.5 24.4 ± 3.1 24.4 ± 3.8 0.97
Hypertension 73.1 % 75.7 % 70.6 % 0.01a
Diabetes mellitus 39.2 % 39.8 % 38.7 % 0.63
Dyslipidemia 70.4 % 70.6 % 70.2 % 0.86
Family history of ischemic heart disease 18.5 % 19.1 % 17.9 % 0.50
Smoking 45.1 % 47.6 % 42.5 % 0.03a
History of coronary revascularization (PCI or CABG) 27.7 % 26.8 % 28.6 % 0.38
Total cholesterol (mg/dl) 190.7 ± 35.8 190.7 ± 34.2 190.7 ± 37.4 0.98
Triglycerides (mg/dl) 146.8 ± 95.5 155.4 ± 100.2 138.4 ± 90.1 <0.01a
Low-density lipoprotein cholesterol (mg/dl) 111.2 ± 30.8 111.1 ± 29.9 111.2 ± 31.8 0.94
High-density lipoprotein cholesterol (mg/dl) 51.7 ± 16.5 50.0 ± 15.1 53.4 ± 17.6 <0.01a
Hemoglobin A1c (%) 6.3 ± 1.1 6.2 ± 0.9 6.3 ± 1.2 0.44
Serum creatinine (mg/dl) 0.88 ± 0.29 0.88 ± 0.27 0.87 ± 0.31 0.41
Estimated glomerular filtration rate (ml/min/1.73 m2) 68.7 ± 17.7 67.0 ± 16.4 70.2 ± 18.7 <0.01a
EPA (μg/dl) 73.9 ± 44.0 93.5 ± 47.9 54.2 ± 28.5 <0.01a
EPA/AA <0.01a
Mean 0.49 ± 0.30 0.66 ± 0.32 0.32 ± 0.17
Median 0.425 0.588 0.290
DHA (μg/dl) 143.4 ± 52.8 170.9 ± 53.0 115.9 ± 35.3 <0.01a
DHA/AA <0.01a
Mean 0.95 ± 0.38 1.22 ± 0.36 0.68 ± 0.15
Median 0.903 1.143 0.706
DGLA (μg/dl) 33.2 ± 12.3 30.8 ± 11.5 35.6 ± 12.6 <0.01a
AA (μg/dl) 157.4 ± 49.5 142.1 ± 33.8 172.8 ± 57.4 <0.01a
Statins 53.1 % 48.7 % 57.5 % <0.01a
Antiplatelet agents 62.7 % 67.5 % 58.0 % <0.01a
Renin angiotensin system inhibitor (ACE-I and ARB) 50.7 % 50.1 % 51.4 % 0.59
Calcium channel blockers 45.6 % 47.8 % 43.5 % 0.08
Beta blockers 38.6 % 39.6 % 37.6 % 0.43
Hypoglycemic agents 21.1 % 21.0 % 21.1 % 0.95
Values are mean ± standard deviation, or percentage, aindicates statistical signficance, PCI = Percutaneous coronary intervention, CABG coronary artery bypass
grafting, EPA/AA eicosapentaenoic acid to arachidonic acid ratio, DHA/AA docosahexaenoic acid to arachidonic acid ratio, DGLA dihomo-gamma-linolenic acid,
ACE-I angiotensin converting enzyme inhibitor, ARB angiotensin II receptor blocker
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Table 2 shows the baseline clinical characteristics ac-
cording to gender. The patient age, the levels of total
cholesterol, LDL-cholesterol, and HDL-cholesterol were
significantly higher in the female group than in the male
group. The prevalence of DM, smoking, and family his-
tory of CAD as well as the use of antiplatelet agents and
beta blockers was significantly lower in the female group
than in the male group. The levels of BMI, TG,
hemoglobin A1c, and Cr were significantly lower in the
high DHA/AA ratio group than in the low DHA/AA ra-
tio group.
Table 3 shows the relationship between the DHA/
AA ratio (≥0.903/<0.903) and ACS in the various sub-
groups. From interaction tests in 10 different sub-
group analyses, the most significant difference in the
adjusted log odds ratios was between men and
women (p = 0.01), followed by the difference between
those with and without HT (p = 0.06). A high DHA/
AA ratio was significantly associated with a low risk
of ACS among men in particular (adjusted odds ratio
= 0.389; 95 % CI: 0.211–0.716), whereas it was associ-
ated with a high risk of ACS in women, although this
latter result was not statistically significant (adjusted
odds ratio = 3.820; 95 % CI: 0.718–20.325). These as-
sociations were in opposite directions, but of similar
magnitude (i.e., 1/0.389 = 2.57). In all of the other
groups, except for the female subgroup and the sub-
group without DL, a high DHA/AA ratio (≥0.903)
tended to have a negative association for ACS
(Table 3).
Figure 1 shows the prevalence of ACS by a quartile of
DHA/AA ratio in all patients. The prevalence of ACS in
quartile 1 was 9.5 % (41/433), in quartile 2 was 10.4 %
(45/433), in quartile 3 was 8.6 % (38/434), and in
Table 2 Baseline clinical characteristics according to gender
Male (n = 1348) Female (n = 385) P-value
Age (years) 63.6 ± 11.1 67.5 ± 11.5 <0.01a
Body mass index (kg/m2) 24.5 ± 3.2 24.0 ± 4.3 0.02a
Hypertension 72.6 % 75.1 % 0.36
Diabetes mellitus 41.5 % 31.4 % <0.01a
Dyslipidemia 70.5 % 70.1 % 0.89
Family history of ischemic heart disease 20.0 % 13.2 % <0.01a
Smoking 53.6 % 47.6 % <0.01a
History of coronary revascularization (PCI or CABG) 31.2 % 15.6 % <0.01a
Total cholesterol (mg/dl) 187.1 ± 34.8 202.7 ± 36.8 <0.01a
Triglycerides (mg/dl) 151.8 ± 99.9 130.3 ± 77.6 <0.01a
Low-density lipoprotein cholesterol (mg/dl) 109.8 ± 30.3 115.6 ± 32.2 <0.01a
High-density lipoprotein cholesterol (mg/dl) 48.8 ± 14.3 61.3 ± 19.4 <0.01a
Hemoglobin A1c (%) 6.3 ± 1.1 6.1 ± 1.0 0.02a
Serum creatinine (mg/dl) 0.93 ± 0.29 0.71 ± 0.23 <0.01a
Estimated glomerular filtration rate (ml/min/1.73 m2) 68.8 ± 17.4 68.4 ± 18.7 0.72
EPA (μg/dl) 73.7 ± 43.2 74.4 ± 47.0 0.76
EPA/AA 0.50 ± 0.31 0.46 ± 0.29 0.01a
DHA (μg/dl) 141.8 ± 52.5 149.0 ± 53.2 0.01a
DHA/AA 0.96 ± 0.40 0.92 ± 0.33 0.06
DGLA (μg/dl) 32.7 ± 12.5 35.0 ± 11.5 <0.01a
AA (μg/dl) 154.4 ± 51.3 167.8 ± 41.3 <0.01a
Statins 53.0 % 53.2 % 0.95
Antiplatelet agents 67.9 % 44.7 % <0.01a
Renin angiotensin system inhibitors (ACE-I and ARB) 50.7 % 50.6 % 1.00
Calcium channel blockers 44.4 % 50.1 % 0.04a
Beta blockers 41.7 % 27.8 % <0.01a
Hypoglycemic agents 22.0 % 17.9 % 0.08
Values are mean ± standard deviation, or percentage, aindicates significance, PCI Percutaneous coronary intervention, CABG coronary artery bypass grafting, EPA/
AA eicosapentaenoic acid to arachidonic acid ratio, DHA/AA docosahexaenoic acid to arachidonic acid ratio, DGLA dihomo-gamma-linolenic acid, ACE-I angiotensin
converting enzyme inhibitor, ARB angiotensin II receptor blocker
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Table 3 Relationship between DHA/AA (≥0.903) and ACS, subgroup analysis
Subgroup DHA/AA ACS N Prevalence Crude OR (95 % CI) Adjusted OR(95 % CI) P-value for interaction
Male ≥0.903 47 688 6.8 % 0.572 (0.391, 0.838) 0.389 (0.211, 0.716) 0.01a
<0.903 75 660 11.4 %
Female ≥0.903 18 179 10.1 % 1.982 (0.910, 4.317) 3.820 (0.718, 20.325)
<0.903 11 206 5.3 %
Age ≥65 ≥0.903 43 539 8.0 % 0.842 (0.528, 1.343) 0.658 (0.329, 1.317) 0.23
<0.903 35 375 9.3 %
Age <65 ≥0.903 22 328 6.7 % 0.620 (0.368, 1.044) 0.312 (0.115, 0.846)
<0.903 51 491 10.4 %
Diabetes mellitus, yes ≥0.903 25 345 7.2 % 0.576 (0.341, 0.973) 0.424 (0.197, 0.915) 0.31
<0.903 40 335 11.9 %
Diabetes mellitus, no ≥0.903 40 522 7.7 % 0.875 (0.562, 1.361) 0.758 (0.338, 1.700)
<0.903 46 531 8.7 %
Hypertension, yes ≥0.903 51 656 7.8 % 0.819 (0.552, 1.216) 0.706 (0.377, 1.320) 0.06a
<0.903 57 611 9.3 %
Hypertension, no ≥0.903 14 211 6.6 % 0.554 (0.285, 1.078) 0.162 (0.039, 0.670)
<0.903 29 255 11.4 %
Dyslipidemia, yes ≥0.903 46 612 7.5 % 0.656 (0.443, 0.973) 0.447 (0.237, 0.845) 0.15
<0.903 67 608 11.0 %
Dyslipidemia, no ≥0.903 19 255 7.5 % 1.013 (0.523, 1.961) 1.139 (0.368, 3.527)
<0.903 19 258 7.4 %
Smoking history, yes ≥0.903 40 413 6.8 % 0.652 (0.420, 1.010) 0.475 (0.218, 1.031) 0.68
<0.903 52 368 14.1 %
Smoking history, no ≥0.903 25 454 5.5 % 0.795 (0.467, 1.355) 0.598 (0.265, 1.350)
<0.903 34 498 6.8 %
Family history of IHD, yes ≥0.903 9 166 5.4 % 0.298 (0.134, 0.661) 0.621 (0.174, 2.219) 0.76
<0.903 25 155 16.1 %
Family history of IHD, no ≥0.903 56 701 8.0 % 0.925 (0.633, 1.351) 0.499 (0.266, 0.939)
<0.903 61 711 8.6 %
Chronic kidney disease, yes ≥0.903 18 236 7.6 % 0.607 (0.317, 1.161) 0.738 (0.277, 1.963) 0.40
<0.903 23 192 12.0 %
Chronic kidney disease, no ≥0.903 21 439 4.8 % 0.582 (0.337, 1.002) 0.439 (0.219, 0.880)
<0.903 40 503 8.0 %
Obesity (BMI ≥25), yes ≥0.903 23 319 7.2 % 0.707 (0.402, 1.242) 0.909 (0.376, 2.196) 0.19
<0.903 31 313 9.9 %
Obesity (BMI <25), no ≥0.903 42 516 8.1 % 0.777 (0.508, 1.189) 0.425 (0.206, 0.877)
<0.903 53 518 10.2 %
History of coronary revascularization, yes ≥0.903 32 232 13.8 % 0.742 (0.452, 1.217) 0.488 (0.243, 0.979) 0.84
<0.903 44 248 17.7 %
History of coronary revascularization, no ≥0.903 33 635 5.2 % 0.752 (0.470, 1.203) 0.554 (0.211, 1.454)
<0.903 42 618 6.8 %
aindicates statistical signficance for interaction (P < 0.10), OR = odds ratio, CI = confidence interval, ACS = acute coronary syndrome, DHA/AA = docosahexaenoic
acid to arachidonic acid ratio, IHD = ischemic heart disease, BMI = body mass index
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quartile 4 was 6.3 % (27/433). Figure 2 shows the preva-
lence of ACS by a quartile of DHA/AA ratio for men,
revealing a prevalence of ACS in quartile 1 of 10.5 %
(35/333), in quartile 2 of 12.2 % (40/327), in quartile 3 of
7.4 % (25/338), and in quartile 4 of 6.3 % (22/350). Fig-
ure 3 then shows the prevalence of ACS by a quartile of
DHA to AA ratio for women, revealing a prevalence of
ACS in quartile 1 of 6.0 % (6/100), in quartile 2 of 4.7 %
(5/106), in quartile 3 of 13.5 % (13/96), and in quartile 4
of 6.0 % (5/83). Thus, there were clearly different trends
of ACS risk for the DHA/AA ratio between men and
women.
Discussion
Previous studies have demonstrated that treatment with
EPA can reduce the risk of CAD [1, 2]. The Japan EPA
Lipid Intervention Study (JELIS) proved that EPA ad-
ministration could reduce residual risk in statin-treated
Fig. 1 The prevalence of acute coronary syndrome by DHA to AA ratio quartile in all patients. DHA = docosahexaenoic acid,
AA = arachidonic acid
Fig. 2 The prevalence of acute coronary syndrome DHA to AA ratio quartile in men. DHA = docosahexaenoic acid, AA = arachidonic acid
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patients [1]. In a sub-analysis of the JELIS, EPA adminis-
tration had a beneficial effect for coronary or cerebro-
vascular events, particularly in statin-treated patients
with abnormal TG and HDL- cholesterol levels, as well
as in patients with glucose intolerance, a history of
stroke, and those with CAD [13–16]. These data sug-
gested the importance of supplemental EPA for reducing
any residual risk after statin treatment. However, the
clinical usefulness of DHA treatment remains unclear,
partially because no purified DHA-only agent has been
launched in the clinical setting.
We report that a low EPA/AA ratio is associated with
CAD and ACS, which is consistent with previous reports
[3–6]. Therefore, an imbalance in the ratio of omega-3
to omega-6 PUFAs in the serum might be one of the re-
sidual risks. Several studies have reported the association
between coronary events and the EPA/AA and DHA/AA
ratios. Ninomiya et al. showed that a low EPA/AA ratio
but not the DHA/AA ratio was associated with a risk of
cardiovascular disease in subjects with higher levels of
high-sensitivity C-reactive protein [4]. Domei et al. eval-
uated the relationship between the EPA/AA or DHA/
AA ratios and major adverse cardiac events in patients
who underwent elective percutaneous coronary inter-
vention. They concluded that those with a higher EPA/
AA ratio (>0.4037) had significantly lower major adverse
cardiac events than those with a low EPA/AA ratio, but
not DHA/AA, ratio [5]. Lee et al. demonstrated that
high EPA levels rather than DHA were significantly as-
sociated with cardiovascular mortality [17]. EPA bio-
logically competes with AA and works as a central
substance for anti-inflammation reducing prostaglandins
or leukotrienes, which are induced by AA. We believe
that the clinical assessment of DHA/AA is also import-
ant because DHA and EPA have anti-inflammatory
effects.
In contrast, a previous study has reported that high
plasma DHA is associated with reduced progression of
coronary atherosclerosis in patients with CAD [18]. In a
clinical study using virtual histology intravascular ultra-
sound, the DHA/AA ratio had a stronger negative rela-
tionships with changes in plaque volume than the EPA/
AA ratio in statin-treated patients with CAD [19]. Previ-
ous studies have also reported that the DHA level has a
strong inverse association with intima-media thickness
when compared with the EPA level [20, 21]. DHA rather
than EPA has also been shown to lower ambulatory
blood pressure and heart rate [22]. Moreover, other
studies have demonstrated numerous beneficial effects
of DHA, including microcirculation [23], antiplatelet
[24], and anti-inflammation effects [25]. However, differ-
ences in the current results for EPA and DHA may be
due to differences in participants, ethnic groups, and
concomitant medications. As demonstrated in the
present study, we may need to focus on the levels of
both the EPA/AA ratio and the DHA/AA ratio.
Although EPA and DHA are both omega-3 PUFAs,
more attention has been focused on the differences in
their physiological and pharmacological effects [7]. Al-
though the detailed mechanisms are yet to be clarified,
both EPA and DHA have anti-inflammatory, anti-
thrombotic, TG-lowering, inhibition of platelet aggrega-
tion, improvement of endothelial function, and plaque
stabilization effects [26–29]. These beneficial effects
Fig. 3 The prevalence of acute coronary syndrome by DHA to AA ratio quartile in women. DHA = docosahexaenoic acid, AA = arachidonic acid
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might be additive for anti-atherogenesis in patients with
high EPA/AA and DHA/AA ratios. Further investigation
is needed to clarify these issues.
Several clinical studies have previously reported gen-
der differences in the relationship between omega-3
PUFAs and cardiovascular mortality [17, 30, 31]. In
2013, The Risk and Prevention Study Collaboration
Group conducted a double-blind, placebo-controlled
clinical trial to evaluate the preventive effects of omega-
3 PUFAs (EPA and DHA) on cardiovascular mortality in
12,513 patients with multiple cardiovascular risk factors
[30]. Although null results were observed for the pri-
mary and secondary endpoints, a gender difference was
observed in a subgroup analysis. Omega-3 PUFAs
showed preventive effects for cardiovascular events in
women (hazard ratio, 0.82; 95 % CI, 0.67–0.99) but not
in men (hazard ratio, 1.04; 95 % CI, 0.92–1.17). Lee et al.
reported a stronger association between high plasma
EPA level and mortality reduction among women with
acute myocardial infarction than among men [17]. In a
Finnish study, higher fish consumption was related to a
decreased risk of coronary heart disease among women,
but no significant relationship was observed among men
[31]. Although previous studies have reported that
omega-3 PUFAs were significantly associated with car-
diovascular events and mortality in women, we found a
significant relationship between the DHA/AA ratio and
ACS events in men. While gender differences can par-
tially be explained by the effects of sex hormones, the
precise mechanisms that lead to gender differences are
not fully understood. It is also not clear whether gender
altered the effects of omega-3 PUFAs on cardiovascular
mortality. In particular, reports that focus on gender dif-
ferences in the relationship between the DHA/AA ratio
and cardiovascular events are rare.
We also assessed the association between serum AA
level and medications and found that the administration
of statins, antiplatelet agents, beta blockers, and
hypoglycemic agents was significantly associated with
serum AA levels. The relationship between statin admin-
istration and AA cascade has already been reported [32],
and it is well known that aspirin prevents antithrombotic
events through affecting the AA cascade; [33] thus, it
could reduce serum AA levels. The relationships be-
tween beta blocker, hypoglycemic agents, and AA have
still not been clarified and need further studies.
It has been reported that human immunodeficiency
virus (HIV) infection is a prognostic indicator for recur-
rent thrombotic events [34]. However, we believe that it
has a relatively low impact on the results of our study
because the incidence of HIV infection is quite low in
Japan.
There are several limitations of the present study.
First, because it was conducted in the metropolitan
Tokyo area, the results are not necessarily applicable to
patients living in rural areas or foreign countries. Sec-
ond, we were unable to prove a cause-effect relationship
because of the cross-sectional design of our study. Third,
as the duration of the study was over 7 years, medical
advances during this period might have affected the
study results. Fourth, assessment of dietary habits is im-
portant because plasma fatty acid profile depends upon
their dietary habits. The assessment was not conducted
in this study. However, PUFAs, such as EPA and DHA,
are not sufficiently produced in the human body. We be-
lieve that the levels of essential plasma fatty acids, such
as EPA and DHA, must be influenced by dietary habits.
Fifth, fatty acid profiles were assessed only in four sub-
sets (EPA, DHA, DGLA, and AA), and complete fatty
acid profiles were not presented. Sixth, we have not con-
ducted an assessment of inflammatory cytokines in this
study. Inflammatory cytokines reduction in the plasma
was observed. Dietary intake of omega-3 fatty acids cor-
relates with the decrease in inflammatory cytokines in
the plasma [35]. Seventh, the red blood cell lipid profile
is known to have a significant correlation between serum
lipid profile and ACS [36]. We should have evaluated be-
tween them. Eighth, because the data in the present
study is male dominant (close to 80 %), a bias from the
patient cohort or study design might be associated with
these results. Ninth, in the present study, fasting blood
samples from patients with ACS were collected during
admission. In the early stage of ACS, the serum fatty
acid profiles would possibly be altered [37]. Finally, we
also enrolled the patients who had any coronary inter-
vention and/or coronary artery bypass grafting due to
stable angina. These patients may have less incidence of
ACS because of their medical therapy. A large-scale
multicenter prospective study is necessary to validate the
results of this study.
The present study showed that the DHA/AA ratio was
more effective for risk stratification due to the ACS
events and that the relationship of EPA/AA ratio with
ACS events was not significant. In our previous report
[6], patients with a medical history of percutaneous cor-
onary intervention, coronary artery bypass grafting, and
myocardial infarction were excluded, whereas those with
past coronary revascularization were included in the
present study. In a meta-analysis of randomized
placebo-controlled trials of EPA vs DHA intervention,
both EPA and DHA reduced TG, with a greater reduc-
tion seen with DHA. DHA, but not EPA, also raised
HDL-cholesterol [38]. There are several reported mecha-
nisms by which the differences between EPA and DHA
treatment may affect lipid metabolism. EPA induces the
reduction of hepatic lipogenesis with a more potent per-
oxisome proliferator-activated receptor-alpha effect,
whereas DHA enhances very-low-density lipoprotein
Nishizaki et al. BMC Cardiovascular Disorders  (2016) 16:143 Page 8 of 10
(VLDL) lipolysis and increases HDL and large LDL par-
ticles [39]. Several studies demonstrate that DHA, but
not EPA, reduces the apolipoprotein C-III concentration
[40, 41]. Apolipoprotein C-III particularly inhibits the
actions of lipoprotein lipase and hepatic lipase, which
slow TG hydrolysis [42]. By regulating different hepatic
transcription factors than EPA, DHA reduces apolipo-
protein C-III production, resulting in enhanced conver-
sion of VLDL to LDL to reduce TG [39, 43]. However,
until now, there was no study that investigated the dif-
ference between EPA alone and EPA/DHA combination
on clinical outcomes, including cardiovascular events
and total mortality. The bio-reactive function of EPA or
DHA may be different among the characteristically dif-
ferent groups of patients. In addition, the data of EPA/
AA and DHA/AA ratio was not strongly, but moderately
correlated (data not shown) in the present study. EPA
and DHA may show a parallel function in the body, but
data collected from a real clinical setting, as the present
study, do not necessarily show a notable correlation.
Further studies should be conducted to clarify these
mechanisms. In the near future, we believe that EPA or
DHA will be appropriately administered to patients, de-
pending on their clinical background.
Conclusions
The present study showed that the relationship between
the DHA/AA ratio and ACS differed with the sex of par-
ticipants who evaluated the serum levels of PUFAs in
cardiology departments. Those men with low DHA/AA
ratios had 2.57 times more ACS than those with a high
DHA/AA ratio. In contrast, a reverse association of
similar magnitude was found among women, although
this was not statistically significant. In the present study,
healthy subjects were not the focus of attention. Further
studies are needed to clarify the association between
DHA/AA ratio and the risk of ACS in apparently healthy
subjects.
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